Myriad Genetics (MYGN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Myriad Genetics (MYGN) is Neutral.

The composite score behind that read is -0.06, weighing +0.16 of bullish evidence against -0.26 bearish.

Myriad Genetics last closed at $4.31, +2.62% on the session.

Against the IVW growth benchmark the position is +1.82% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

18 graded predictions for MYGN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Myriad Genetics in the 23rd percentile on return on equity, where 100 is best.

Myriad Genetics is classified under Health Care / Biotechnology, with a market capitalisation of $401.73M.

StockMap tracks Myriad Genetics as the 195th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Myriad Genetics ranks 167th of 381 in the group, against a group median of -0.08.